REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

REGENXBIO reports robust earnings, eyes gene therapy market expansion

REGENXBIO's Q4 2022 earnings call highlighted strong financial performance, progress in gene therapy development, and strategic collaborations with AbbVie.
While challenges like precise dosing and program validation exist, the company's focus on innovation and market potential present significant growth opportunities.
With a robust pipeline, efficient development processes, and a commitment to addressing unmet medical needs, REGENXBIO is well-positioned for continued success in the gene therapy market.
Investors can look forward to potential revenue growth from royalty recognition and license agreements, supported by the company's solid financial foundation and strategic initiatives.

REGENXBIO reports solid Q1 earnings, advances gene therapy initiatives

REGENXBIO's Q1 2023 earnings call showcased strong financial performance, progress in gene therapy, and strategic partnerships, positioning the company for future growth.
Challenges such as patient exclusions in clinical trials and decision-making on pivotal studies require careful navigation and operational focus.
Opportunities in partnership milestones, regulatory paths, and market differentiation present avenues for continued success and innovation in the gene therapy space.

REGENXBIO advances AAV therapeutics with strong Q2 performance

REGENXBIO's Q2 performance reflects progress in AAV therapeutics and positive clinical outcomes, supported by a strong financial position and strategic focus on urgent medical needs.
While facing challenges related to competitive pressures and program timelines, the company's commitment to innovation and regulatory compliance positions it well for future growth.
Opportunities lie in differentiated treatment approaches, improved product efficacy, and expedited regulatory pathways, signaling potential for market leadership and patient impact.

REGENXBIO reports robust Q3 results, eyes sustainable growth post-2025

REGENXBIO's Q3 2023 earnings call highlighted strong financial performance, clinical progress, and strategic initiatives, showcasing a promising outlook for the company.
While facing challenges in aligning financial expectations and operational performance, REGENXBIO's focus on cost-saving measures and program advancements presents growth opportunities.
The company's commitment to patient impact, regulatory excellence, and shareholder value creation underpin its position as a key player in the biopharmaceutical industry.

REGENXBIO reports robust earnings, focuses on AAV innovation and growth

REGENXBIO's Q4 2023 earnings call highlighted strong financials, exciting program progress, and a focus on innovation in AAV therapeutics for long-term value creation.
While challenges exist in navigating AAV development complexity and operational demands, the company's proactive approach and financial strength position it well for growth.
Opportunities lie in leveraging cash reserves for accelerated development, engaging stakeholders for strategic insights, and exploring enhancements in therapeutic benefits.

REGENXBIO reports strong Q2 results, poised for program advancements

REGENXBIO's Q2 performance showcased advancements in key programs, bolstered by a strong financial position and positive clinical data.
While challenges exist in patient recruitment and regulatory strategies, opportunities for market approvals and portfolio expansion are on the horizon.
Strategic planning and successful execution will be crucial for REGENXBIO to capitalize on its strengths and navigate potential obstacles.

REGENXBIO reports robust Q3 results and advances gene therapy programs

REGENXBIO's strong financial position and progress in key programs demonstrate a promising outlook for the company's growth and innovation.
The company's focus on rare diseases and ophthalmology positions it as a leader in gene therapy treatments with significant market potential.
Addressing challenges related to program durability, market competition, and regulatory complexities will be crucial for sustaining growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regenxbio: A Growth Stock For The Coronavirus Bear Market

REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q4 2019 Results - Earnings Call Transcript

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Regenxbio (RGNX) Q4 Earnings Expected to Decline

Regenxbio: Fairly Valued Given The Current Risks But Could Have Eye-Watering Upside

Regenxbio: Revisiting This Gene Therapy 'Picks And Shovels' Play

Regenxbio: Amid Temporary Difficulty Is A Buying Opportunity

Regenxbio stock toppled below its 50-day moving average early Wednesday after the U.S. Food and Drug Administration put one of the biotech company's gene therapy candidates on hold.

This Biotech Dived After The FDA Put Its Gene Therapy Study On Pause

REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call Transcript

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Illumina

Intellia Therapeutics

Invitae

Veracyte

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

8 Undervalued Biotech Stocks to Watch Now

Clearside Biomedical

ALPHARETTA, Ga., Oct.  30, 2019  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that REGENXBIO Inc. (Nasdaq: RGNX) has exercised its option under the previously announced option and license agreement to license Clearside’s proprietary, in-office SCS Microinjector™ for the delivery of adeno-associated virus (AAV)-based therapeutics, including but not limited to RGX-314 delivery to the suprachoroidal space to potentially treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other conditions for which chronic anti-vascular endothelial growth factor (anti-VEGF) treatment is currently the standard of care.

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections

Denali Therapeutics

These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.

Big Pharma Has Mad Love For These 2 Biotechs

Adverum Biotechnologies

Kodiak Sciences Inc

Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.

3 Blindness-Fighting Biotech Stocks That Could Surge This Week

REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%

Amgen

Vertex Pharmaceuticals

Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.

Three Top Biotech Stocks, to Buy Right Now

President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T.

Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares

Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q2 2019 Results - Earnings Call Transcript

Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $742,350 of Shares

Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?

As a leading gene therapy innovator, Regenxbio is undergoing many strong fundamental developments.

Regenxbio: More To Come After Zolgensma Approval

Regenxbio expects to obtain royalty payments from Novartis for Zolgensma after it was approved by the FDA to treat patients with spinal muscular atrophy.

With FDA Approval Of Zolgensma, Regenxbio Sets Out For First Revenue Stream

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%

Novartis

A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.

Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio

Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q1 2019 Results - Earnings Call Transcript

As lucrative investments, gene therapy companies also are delivering hope for countless patients worldwide.

News for REGENXBIO Stock (RGNX)